arrow
B

Benjamin Yarnoff

pfizer usa
H指数:13
被引数:815

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States

辉瑞-生物科技COVID-19疫苗(LP.8.1-adapted,2025/2026配方)在美国18岁及以上高风险成人群体中的成本效益、公共卫生影响及预算影响

2026-05-230
OA
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

尼塞vimab和Clesrovimab在美国预防婴儿呼吸道合胞病毒下呼吸道疾病的经济性:一项模型研究

2026-02-260
OA
Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort

婴儿呼吸道合胞病毒(RSV)疾病预防方案的公共卫生影响比较:美国出生队列的静态决策模型

2025-12-310
PRE